Ask what the evidence actually studied.

Bring the claim back to a study question

• Was this tested in people with the concern I have?
• Did the study use this exact medicine, as a pill, a shot or the same way I would receive it?
• What was it compared with, and what change was measured?
• How long did the study follow people?
• What is still unknown about applying that result to me?

Ask to see the passage behind the headline

Take the exact claim to the visit. Ask the clinician to point to the study passage that supports it, then explain the result without the headline.

If a paper is offered, ask what kind of study it was. Keep “tested in people” and “tested for my concern” as separate questions.

A meeting is not a product approval

For a specially prepared medicine, rules limit which raw ingredients may be used. One way an ingredient can qualify is to appear on FDA’s list of allowed ingredients.

An FDA advisory committee is a group that advises the agency. As of September 26, 2026, its vote alone could not change the allowed-ingredient list. FDA had to finish its formal rule-making process to change that list.

If a headline names a meeting, ask what final action followed it. A discussion alone does not answer whether your proposed medicine may be prepared.

Keep an unanswered question visible

Some names in online peptide offers are BPC-157, ipamorelin, epitalon and MOTS-c. A search of FDA’s drug-application records on September 26, 2026 found no application for any of those names.

That search found no approved US medicine under those names. It does not show that FDA refused an application, or settle whether a pharmacy may prepare a particular product.

Nor does a missing approval record tell you what a study found for your health concern. Ask for the evidence behind that separate claim.

It is fair to leave the visit with an open question. Write down what evidence is missing and ask how that gap affects the options being discussed.

Keep the evidence questions on your visit sheet